{
    "id": "eb93bf1e-9a04-48ff-9ed7-94473bcd5552",
    "indications": "ondansetron tablets indicated prevention nausea vomiting associated : highly emetogenic cancer chemotherapy , including cisplatin greater equal 50 mg/m2 . initial repeat courses moderately emetogenic cancer chemotherapy . radiotherapy patients receiving either total body irradiation , single high-dose fraction abdomen , daily fractions abdomen ondansetron tablets also indicated prevention postoperative nausea and/or vomiting .",
    "contraindications": "full prescribing information recommended adults pediatrics ( 2 ) patients severe hepatic impairment : exceed total daily dose 8 mg ( 2.2 , 8.6 )",
    "warningsAndPrecautions": "ondansetron tablets ondansetron tablets ondansetron tablets usp , 4 mg ( ondansetron hydrochloride usp , equivalent 4 mg ondansetron ) white , round , biconvex , film coated tablets debossed “ r ” one side “ 153 ” side supplied : overbagged 10 film coated tablets per bag , ndc 55154-3551-0 ondansetron tablets usp , 8 mg ( ondansetron hydrochloride usp , equivalent 8 mg ondansetron ) yellow , round , biconvex , film coated tablets debossed “ r ” one side “ 154 ” side supplied : overbagged 10 film coated tablets per bag , ndc 55154-7879-0 warning : unit dose packages child resistant intended institutional . keep drugs reach children . store 20°-25°c ( 68°-77°f ) ( usp controlled room temperature ) . dispense tight container defined usp . store blisters cartons .",
    "adverseReactions": "ondansetron contraindicated patients : •known hypersensitivity ( e.g . , anaphylaxis ) ondansetron components formulation [ ( 6.2 ) ] •receiving concomitant apomorphine due risk profound hypotension loss consciousness",
    "ingredients": [
        {
            "name": "ONDANSETRON HYDROCHLORIDE",
            "code": "NMH84OZK2B"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        }
    ],
    "organization": "Cardinal Health 107, LLC",
    "name": "ondansetron",
    "effectiveTime": "20250505",
    "indications_original": "Ondansetron  tablets are indicated for the prevention of nausea and vomiting associated with: \n                  \n                     \n                         highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m2 .\n                     \n                          initial and repeat courses of moderately emetogenic cancer chemotherapy.\n                     \n                         radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen\n                  \n                  Ondansetron tablets are also indicated for the prevention of postoperative nausea and/or vomiting.",
    "contraindications_original": "See full prescribing information for the recommended dosage in adults and pediatrics (2) Patients with severe hepatic impairment: do not exceed a total daily dose of 8 mg ( 2.2 , 8.6 )",
    "warningsAndPrecautions_original": "Ondansetron Tablets\n                  \n                  Ondansetron Tablets Ondansetron tablets USP, 4 mg (ondansetron hydrochloride USP, equivalent to 4 mg of ondansetron) are white, round, biconvex, film coated tablets debossed “R” on one side and “153” on other side and are supplied:\n                  Overbagged with 10 film coated tablets per bag, NDC 55154-3551-0\n                  Ondansetron tablets USP, 8 mg (ondansetron hydrochloride USP, equivalent to 8 mg of ondansetron) are yellow, round, biconvex, film coated tablets debossed “R” on one side and “154” on other side and are supplied:\n                  Overbagged with 10 film coated tablets per bag, NDC 55154-7879-0\n                  WARNING: These Unit Dose packages are not child resistant and are Intended for Institutional Use Only. Keep this and all drugs out of the reach of children.\n                  Store at 20°-25°C (68°-77°F) (See USP Controlled Room Temperature). Dispense in tight container as defined in the USP. Store blisters in cartons.",
    "adverseReactions_original": "Ondansetron is contraindicated in patients: \n                  \n                     \n                        •known to have hypersensitivity (e.g., anaphylaxis) to ondansetron or any of the components of the formulation [see Adverse Reactions (6.2)]\n                     \n                     \n                        •receiving concomitant apomorphine due to the risk of profound hypotension and loss of consciousness"
}